

Heterogeneity in predisposition of hepatic cells to be induced into pancreatic endocrine cells by PDX-1

Shun Lu, Wei-Ping Wang, Xiao-Fei Wang, Zong-Mei Zheng, Ping Chen, Kang-Tao Ma, Chun-Yan Zhou

Shun Lu, Wei-Ping Wang, Xiao-Fei Wang, Ping Chen, Kang-Tao Ma, Chun-Yan Zhou, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Peking University, Beijing 100083, China
Zong-Mei Zheng, Peking University Stem Cell Research Center, Beijing 100083, China

Supported by the National Natural Science Foundation of China, No. 30240087; the National High Technology Research and Development Program of China, No. 2003AA205090

Co-first-authors: Shun Lu and Wei-Ping Wang

Correspondence to: Professor Chun-Yan Zhou, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Peking University, 38 Xue Yuan Road, Haidian District, Beijing 100083, China. chunyanzhou@bjmu.edu.cn

Telephone: +86-10-82802417 Fax: +86-10-62015582

Received: 2004-05-12 Accepted: 2004-06-24

Abstract

AIM: The role of Pancreatic and Duodenal Homeobox-1 (PDX-1) as a major regulator of pancreatic development determines the function and phenotype of β cell. In this study, potential plasticity of liver cells into pancreatic endocrine cells induced by PDX-1 was evaluated.

METHODS: Human hepatoma cell line HepG2 was stably transfected with mammalian expression plasmid pcDNA3-PDX encoding human PDX-1 gene. Ectopic expression of PDX-1 and insulin were detected by RT-PCR, Western blot and/or immunostaining. PDX-1⁺ HepG2 cells were transplanted under renal capsule of STZ-induced diabetic nude mice ($n = 16$) to examine the inducing effect *in vivo*.

RESULTS: Exogenous PDX-1 transgene was proved to express effectively in HepG2 cell at both mRNA and protein levels. The expression of endogenous insulin and some β cell-specific differentiation markers and transcription factors were not induced in PDX-1⁺ HepG2 cells. When transplanted under renal capsule of STZ-induced diabetic nude mice, PDX-1⁺ HepG2 cells did not generate insulin-producing cells. These data indicated that stable transfected PDX-1 could not convert hepatoma cell line HepG2 to pancreatic cells *in vitro* or *in vivo*. Mature hepatocytes might need much more complicated or rigorous conditions to be shifted to insulin-producing cells.

CONCLUSION: The expression of exogenous PDX-1 is not sufficient to induce relatively mature hepatocytes differentiating into insulin-producing cells.

Key words: PDX-1; HepG2, Insulin; Transgene; Diabetes

Lu S, Wang WP, Wang XF, Zheng ZM, Chen P, Ma KT, Zhou CY. Heterogeneity in predisposition of hepatic cells to be induced into pancreatic endocrine cells by PDX-1. *World J Gastroenterol* 2005; 11(15): 2277-2282

<http://www.wjgnet.com/1007-9327/11/2277.asp>

INTRODUCTION

Insulin-dependent diabetes mellitus (IDDM) is characterized by insulin deficiency due to autoimmune destruction of pancreatic β cells. Gene therapy or cell-replacement therapy might be an optimal strategy^[1,2]. Recently, increasing studies focused on inducing non- β -cell derived cells into surrogate β cells that can produce and secrete insulin, by genetic modification in most cases^[3-5]. In addition to several types of stem cells^[6-8], the most commonly used cell type for this purpose is liver cells^[9-11].

Both liver and pancreas emerge from ventral foregut endoderm and specifically at about the same time during embryonic development. Although different set of transcription factors and specialized gene profiles are expressed in liver and pancreas buds, some gene products are common to both tissues^[12], including the essential factors in glucose sensing machinery, such as GLUT-2 and glucokinase.

As a regulator located upstream in the insulin gene transcription cascade, pancreatic and duodenal homeobox-1 (PDX-1) is considered as a promising candidate transgene in gene therapy for diabetes. PDX-1 was originally identified as an insulin gene transcription factor^[13]. It also activates expression of other islet-enriched genes, including GLUT-2^[14], glucokinase^[15], islet amyloid polypeptide (IAPP)^[16] and somatostatin^[17]. PDX-1 knockout mice led to the loss of the whole pancreas^[18]. Mice carrying PDX-1 deletion developed diabetes^[19]. In humans, patient bearing a mutant PDX-1 gene resulted in agenesis of pancreas at birth^[20]. Taking these together, PDX-1 appears to be a major regulator of pancreatic development and determines the function and phenotype of β cell.

Ferber *et al.* found that ectopic expression of PDX-1 induced expression of endogenous insulin gene in mouse liver^[21]. The same group and another, recently, further demonstrated that PDX-1, as a "master regulator" of directing cell fate, has the sufficient capacity to induce the mature liver cells into pancreatic endocrine cells *in vivo*^[22,23]. However, a recent report from Horb *et al.* failed to convert liver cells to insulin-producing cells with the transient

expression of wild type PDX-1 alone, but it was achieved when PDX-1 gene was fused with a transcriptional activation domain VP16^[24].

Then the intriguing questions are: if PDX-1 can convert some liver cells to pancreatic cells *in vivo*, what if it is introduced into a hepatocyte-derived or a hepatoma cell line like HepG2 *in vitro*? If transient expression of PDX-1 in HepG2 cannot lead to this kind of conversion, how is it expressed in a constitutive way? What will happen if stably transfected PDX-1⁺HepG2 cell is further induced by *in vitro* and *in vivo* environment? In order to elucidate these questions, we established a stable PDX-1-expressing HepG2 cell line and transplanted these cells into STZ-induced diabetic nude mice. We found that insulin and other β cell enriched/specific genes were not activated in PDX-1⁺HepG2 cell line, and no conversion evidence is observed after implantation under renal capsule either.

MATERIALS AND METHODS

Plasmid construction

Human PDX-1 gene coding sequence was amplified by PCR from Human Pancreas Quick-Clone cDNA library (Clontech, Palo Alto, CA) with forward primer 5'-CCATGAACGGCGA GGAGCAGTA and reverse primer 5'-CTGCCTCTCATCGTGGTTCCTG and cloned into pCDNA3 (Invitrogen, Carlsbad, CA), a mammalian expression vector driven by CMV promoter. The construct was designated as pCDNA3-PDX and characterized by restriction analysis and verified by sequencing.

Cell culture and preparation of stable transfectants

HepG2, a human hepatoma-derived cell line, was obtained from ATCC (Rockville, MD) and maintained in Dulbecco's

Modified Eagle's Medium (DMEM), supplemented with 10% heat inactivated fetal bovine serum, 100 U/mL penicillin, 100 μ g/mL streptomycin. To obtain stable transfectants, HepG2 cells were seeded in 24-well plate 24 h before transfection. A total of 0.8 μ g of pCDNA3-PDX plasmid DNA was transfected into cells using lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) following the manufacturer's recommendation. Forty-eight hours after transfection, the cells were diluted and transferred to 10 cm culture plates, cultured with G418-containing medium (500 μ g/mL). The selective medium was changed every 4 d. G418-resistant colonies appeared 3-4 wk after transfection. The single colonies were picked out using clone rings and then subjected to proliferate for further analysis.

RNA isolation and RT-PCR analysis

Total RNA was isolated from single clone derived cells directly from culture plate using TRIzol reagent (Invitrogen, Carlsbad, CA). RNA samples were treated by 10 units of RQ1 Rnase-free Dnase I (Promega, Madison, WI) for 15 min at 37 °C. Reverse transcription was performed following the manufacturer's instructions (Promega, Madison, WI). Primer sequences and PCR conditions are listed in Table 1. PCR was performed using T-gradient thermocycler (Biometra, Gottingen, Germany) and the product was separated using 1.5% agarose gel and visualized with ethidium bromide. Human fetal pancreas was isolated from a 24-wk gestational age embryo from a natural aborted fetus. Permission to use human embryonic tissues was granted by the Ethics Review Board of Peking University.

Western blot analysis

Expressions of PDX-1 and insulin at protein levels in transfected cells were detected using Western blot analysis as previously

Table 1 RT-PCR information: Primer sequences and PCR conditions

Genes	Primer sequences (5'-3')	Products bp	Annealing		Cycles
			°C	s	
PDX-1	F, GTCCTGGAGGAGCCCAAC R, GCAGTCCTGCTCAGGCTC	360	58	60	30
Insulin	F, GCCTTGTGAACCAACACCTG R, GTTGCAGTAGTCTCCAGCTG	261	62	60	30
GLUT-2	F, TGCCACACTCACACAAGAC R, AGATTGTGGGCAGTTCATC	260	54	60	30
Glucokinase	F, CCCGAGGAGAACCACATT R, GGAACCTGCCAGGATCT	208	56	60	30
IAPP	F, GCTGACATTGAAACATTA R, TATACAGGAAATCACTAGAA	360	56	60	30
Somatostatin	F, TGCGCTGTCCATCGTCCT R, GCCATAGCCGGGTTGAGTT	258	60	60	30
E47	F, TCAGGCTGGCTTCCTGTCAG R, CCCTGCCGTATGCCTCACCT	224	62	60	30
NeuroD1	F, GCGTTAGCCTTCATGCGTCT R, GAGGCCCCAGGGTTATGAG	386	60	60	30
Isl-1	F, CGGCTTCAGCAAGAACGACT R, TCTTCTCCGGCTGCTTGTG	290	58	60	30
GAPDH	F, GTCAGTGGTGGACCTGACCT R, AGGGGAGATTCAGTGTGGTG	415	55	60	30

PCR conditions: denaturation at 94 °C for 30 s; annealing as listed in the table; extension at 72 °C for 1 min.

described^[25]. The protein concentrations were determined using Bradford assay. Five microgram of cellular lysate were separated by standard SDS-PAGE and then transferred to nitrocellulose membrane. Goat polyclonal anti-PDX-1 or anti-insulin antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) were used to probe the blot.

Under-renal-capsule transplantation into STZ-induced diabetic nude mice

Male BALB/c nude mice at age 8-10 wk were used in this study. The animal experiment conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institute of Health (NIH Publication No. 85-23, revised 1996). Mice were fasted for 18 h and then treated with STZ (200 mg/kg body weight, i.p., Sigma, St. Louis, MO) freshly dissolved in citrate buffer (pH 4.5). The blood glucose levels were monitored daily by using a Glucotrend[®] glucose detector (Roche Diagnostics, Mannheim, Germany). Seven days after STZ treatment, the mice with stable hyperglycemia (blood glucose levels >20 mmol/L) were selected for operation. Under pentobarbital sodium (35 mg/kg body weight, i.p.) anesthetization, the left kidney was exposed through a lumbar incision and cells (5×10^6 to 1×10^7) resuspended in PBS were injected into subcapsular cavity by using a 100 μ L micro-syringe. The blood glucose level was monitored on 0, 1, 2, 3, 5, 7, 9, 11, 13, 15, 18, 26, 30 d after transplantation. Recipient animals were killed by cervical dislocation 30 d after operation. Kidney and pancreatic tissues were removed and fixed with 10% paraformaldehyde in PBS at 4 °C for 5 h and embedded in OCT compound for immunohistochemical staining.

Immunocytochemistry and immunohistochemistry

Cells were cultured on non-coated glass coverslips for 24 h before immunostaining. After rinsing with PBS thrice, the cells were fixed with acetone/methanol at 4 °C for 15 min, permeabilized with 10 mL/L Triton X-100 in PBS for 10 min, and incubated sequentially with blocking serum, primary antibodies and TRITC or FITC conjugated secondary antibody. The primary antibodies included goat anti-insulin polyclonal IgG (1:200 dilution, Santa Cruz), goat anti-PDX-1 polyclonal IgG (1:100 dilution, Santa Cruz); mouse anti-human nuclei monoclonal antibody (1:200 dilution, Chemicon, Temecula, CA). Fixed tissue sections (8 μ m thick) were also stained with antibodies as mentioned above. The cells and tissue sections were examined under a fluorescence microscope (Olympus, Nagano, Japan).

Statistical analysis

Results are given as mean \pm SD. The one-way ANOVA was performed by SPSS software (SPSS Science, Chicago, Illinois). $P < 0.05$ were considered significant.

RESULTS

Establishment of HepG2 cell line stably expressing PDX-1

To test the feasibility of HepG2 cells differentiating into pancreatic endocrine cell by ectopically expressed PDX-1 gene, HepG2 cells were transfected with pCDNA3-PDX-1 construct and stable transfectants were isolated under G418

selection. A total of 13 individual colonies were isolated and subjected to RT-PCR and Western blot analysis. Five PDX-1 positive colonies were identified. The clone 11 was selected to amplify for further experiments according to its higher expression level of PDX-1 than other clones (data not shown).

There was no obvious difference in the appearance of PDX-1 positive HepG2 cells from their parental cells. The results of RT-PCR and Western blot indicated the expressions of PDX-1 at both mRNA and protein levels in PDX-1⁺HepG2 cells, but not in wild type HepG2 cells (Figure 1). Although less abundant, the expression level of exogenous PDX-1 gene was comparable to that of human fetal pancreas (Figure 1A). Western blot analysis indicated a 46 ku of PDX-1 protein (Figure 1C). The immunocytochemical staining showed that PDX-1 protein was localized mainly in the nuclei of PDX-1⁺HepG2 cells (Figure 2C). These results indicate that we established the HepG2 cells ectopically express PDX-1 gene in the nucleus as expected.




Figure 1 Expression of PDX-1 transgene and other islet-enriched genes in PDX-1⁺HepG2 cell line. RT-PCR analysis was performed to detect the expression of several islet differentiation markers (A) and islet-specific transcriptional factors (B). GAPDH mRNA was amplified as an internal control. Western blot analysis was performed to detect the expression of PDX-1 using anti-PDX-1 antibody on total protein lysis (C). Lane 1: 24-wk human fetal pancreas (positive control); Lane 2: wild type HepG2 cells (negative control); Lane 3: PDX-1⁺HepG2 cells. Data are representative of at least three independent experiments.

Examination of islet specific genes' expression in PDX-1⁺HepG2 cells

To examine the possible changes in gene expression patterns caused by exogenous PDX-1 gene in HepG2, we used RT-PCR to detect the presence of mRNA of insulin, glucokinase, GLUT-2, somatostatin and IAPP. None of these genes could be detected in both PDX-1 transfected and wild type HepG2, contrasted to distinct bands from pancreatic tissue (Figure 1A). Absence of insulin was further confirmed by immunocytochemical staining (Figure 2F) and by Western blot analysis (data not shown). To investigate the possible mechanism of silence of these islet marker genes, Isl-1 and neuroD1/beta2, upstream transactivators of insulin gene, were also detected by RT-PCR. They expressed neither in PDX-1⁺HepG2 cells nor in parental HepG2 cells (Figure 1B).

Cell transplantation under renal capsule in diabetic nude mice

Previous studies^[26] showed that an *in vivo* microenvironment,

such as renal subcapsule, may be advantageous to facilitate the maturation and differentiation of endocrine cells. To examine if PDX-1⁺HepG2 cells could be induced into insulin-producing cells, cell transplantation was performed. BALB/c nude mice were used to exempt implanted cells from immune attack. A total of 5×10^6 - 1×10^7 PDX-1⁺HepG2 cells or wild type HepG2 cells were implanted to renal subcapsular space of STZ-induced diabetic mice ($n = 16$ and 7 , respectively). The average blood glucose level showed no significant difference between two groups, both at above 20 mmol/L (Figure 3). H&E staining and immunohistochemistry of anti-human nuclei antibody showed that the implanted cells were infiltrated into normal mice nephric tissues (Figure 2), indicating the cell viability and proliferation. The implanted cells displayed stable expression of PDX-1 transgene. No expression of insulin was observed in the kidney sections injected with PDX-1⁺HepG2 cells (Figure 2).




Figure 2 *In situ* immunostaining analysis of PDX-1⁺HepG2 cells in culture and after transplantation into nude mice. Representatives are shown (original magnification 200 \times , unless otherwise stated). Anti-PDX-1 fluorescence stains cultured PDX-1⁺HepG2 cells (B), compared to 24-wk human fetal pancreatic islets (A). The ectopically expressed PDX-1 protein locates mainly within nuclear region (C, 400 \times). Parental HepG2 cells serve as a negative control (D). Anti-insulin fluorescence immunostaining indicates positive staining in human

islet positive control (E) but not in PDX-1⁺HepG2 cells (F). H&E staining reveals implanted PDX-1⁺HepG2 cells in section of kidney (G, 100 \times), indicating that these cells infiltrated into nephric tissues and underwent proliferation. Anti-human nuclei antibody staining confirmed that these cells were of human origin (H, green cells). Anti-PDX-1 staining of mice kidney sections showed consistent expression of PDX-1 transgene in these implanted PDX-1⁺HepG2 cells (I), but insulin expression was absent (J).




Figure 3 Blood glucose level of STZ-induced diabetic nude mice after implantation of PDX-1⁺ HepG2 cells under renal capsule. Between 5×10^6 and 1×10^7 PDX-1⁺ HepG2 cells or parental HepG2 cells were injected into subcapsular space. Blood glucose level was measured 0, 1, 2, 3, 5, 7, 9, 11, 13, 15, 18, 26, 30 d after operation. Values are expressed as mean \pm SD for each time point, PDX-1⁺ HepG2 group ($n = 16$) vs HepG2 group ($n = 7$).

DISCUSSION

Liver cells seem to contain remarkable potential to convert into pancreatic cells. During embryogenesis, pancreas and liver arise from adjacent areas in the anterior endoderm. The default fate of ventral foregut endoderm is to become pancreas, but a FGF-like signal released from the cardiac mesoderm diverts the fate of some cells into liver^[12]. This model implied that pancreas and liver, despite distinct phenotype, may share a similar context of gene expression profile but differ in just a few critical “master regulators”. Under certain conditions, the interchange of pancreas and liver then could be possible. Increasing experimental models have been reported to validate this potential. Adult rat hepatic oval stem cells^[27] can be induced into pancreatic endocrine hormone producing cells in high-glucose environment without genetic modification. Ferber *et al.* found^[21] and recently confirmed^[22] that ectopic expression of PDX-1 induced mouse a pluripotent population of progenitor liver cells to produce biologically mature insulin *in vivo* and ameliorated STZ-induced diabetes. To evaluate whether PDX-1 is able to reprogram a human hepatocyte-derived cell line HepG2 into such pancreatic endocrine cells, we established a PDX-1⁺ HepG2 stable expression cell line. As expected, the expression of PDX-1 transgene in PDX-1⁺ HepG2 was comparable to that of human pancreas islet. PDX-1 protein was properly translocated into cell nuclei, as demonstrated by immunostaining and Western blot. Unexpectedly, the expressions of pancreatic β cell specific genes including insulin, glucokinase, GLUT-2 and IAPP were detected neither in transfected cells nor in mice with cell transplanted under renal capsule.

It is well established that insulin gene transcription in β cells results from the formation of a transcription complex comprising E47, NeuroD1, Isl-1, PDX-1^[28], and more recently, Maf A^[29]. In PDX-1⁺ HepG2 cell line, E47 was present as a ubiquitous nuclear factor, but neuroD1 and Isl-1 were absent. Kojima *et al.*^[30] demonstrated that only combined expressions of Isl-1 and PDX-1 could induce immature rat intestinal crypt cell line IEC-6 to produce insulin, which verified the necessity of Isl-1 in insulin

transcription. Recently the same group found that without PDX-1, NeuroD1, or a combination of NeuroD1 and betacellulin gene transfer could induce insulin production in mouse liver and partly or completely reversed diabetes of STZ mice^[23], indicating that NeuroD1 is another essential factor for the normal function of pancreatic β cells. The absence of Isl-1 and NeuroD1 in HepG2 cells might account for the silence of insulin and other islet specific genes in our model.

Two independent studies^[22,23] confirmed that *in vivo* transfer of PDX-1 by adenovirus into mice unambiguously converted some subpopulation of hepatic cells into pancreatic endocrine and exocrine cells. We intend to specify or narrow down our subject to relatively mature hepatocytes. HepG2 cell line shows a large number of properties of differentiated hepatocytes, including expression of albumin, transferrin and transthyretin^[24]. However, the data from our *in vitro* and *ex vivo* models ruled out the possibility of PDX-1-mediated conversion from mature hepatocytes to pancreatic tissues.

There are many different subpopulations of liver stem cells, which stand at various stages of developmental process and express more or less different profiles of transcription factors. We believe that this diversity endows every subpopulation different potential of reacting to stimulus, such as PDX-1 gene transfer, inducing developmental shift to pancreas. Our results proved the stubbornness of mature hepatocytes to PDX-1 induction. Kojima *et al.*^[23] showed that there were definitely some classes of liver cells that could be converted by PDX-1 transfer and diverse plasticity of these cells were observed under the same manipulation. Combining all these data with ours, we propose that more than one type of subpopulations comprising liver may have the potential to incur liver to pancreas conversion, but they require thresholds fundamentally different from each other to initiate this process. Mature hepatocytes, under this consideration, may also be possible to shift to insulin-producing cells under certain but much more complicated or rigorous conditions, which further needs to be defined.

REFERENCES

- 1 **Ramiya VK**, Maraist M, Arfors KE, Schatz DA, Peck AB, Cornelius JG. Reversal of insulin-dependent diabetes using islets generated *in vitro* from pancreatic stem cells. *Nat Med* 2000; **6**: 278-282
- 2 **Bonner-Weir S**, Taneja M, Weir GC, Tatarkiewicz K, Song KH, Sharma A, O'Neil JJ. *In vitro* cultivation of human islets from expanded ductal tissue. *Proc Natl Acad Sci USA* 2000; **97**: 7999-8004
- 3 **Ianus A**, Holz GG, Theise ND, Hussain MA. *In vivo* derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion. *J Clin Invest* 2003; **111**: 843-850
- 4 **Qin XY**, Shen KT, Zhang X, Cheng ZH, Xu XR, Han ZG. Establishment of an artificial beta-cell line expressing insulin under the control of doxycycline. *World J Gastroenterol* 2002; **8**: 367-370
- 5 **Soria B**, Roche E, Berna G, Leon-Quinto T, Reig JA, Martin F. Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice. *Diabetes* 2000; **49**: 157-162
- 6 **Kahan BW**, Jacobson LM, Hullett DA, Ochoada JM, Oberley TD, Lang KM, Odorico JS. Pancreatic precursors and differ-

- entiated islet cell types from murine embryonic stem cells: an *in vitro* model to study islet differentiation. *Diabetes* 2003; **52**: 2016-2024
- 7 **Efrat S**. Generation of insulin-producing cells from stem cells for cell replacement therapy of type 1 diabetes. *Isr Med Assoc J* 2004; **6**: 265-267
- 8 **Zorina TD**, Subbotin VM, Bertera S, Alexander AM, Haluszczak C, Gambrell B, Bottino R, Styche AJ, Trucco M. Recovery of the endogenous β cell function in the NOD model of autoimmune diabetes. *Stem Cells* 2003; **21**: 377-388
- 9 **Tuch BE**, Szymanska B, Yao M, Tabiin MT, Gross DJ, Holman S, Swan MA, Humphrey RK, Marshall GM, Simpson AM. Function of a genetically modified human liver cell line that stores, processes and secretes insulin. *Gene Ther* 2003; **10**: 490-503
- 10 **Burkhardt BR**, Loiler SA, Anderson JA, Kilberg MS, Crawford JM, Flotte TR, Goudy KS, Ellis TM, Atkinson M. Glucose-responsive expression of the human insulin promoter in HepG2 human hepatoma cells. *Ann N Y Acad Sci* 2003; **1005**: 237-241
- 11 **Thule PM**, Liu JM. Regulated hepatic insulin gene therapy of STZ-diabetic rats. *Gene Ther* 2000; **7**: 1744-1752
- 12 **Deutsch G**, Jung J, Zheng M, Lora J, Zaret KS. A bipotential precursor population for pancreas and liver within the embryonic endoderm. *Development* 2001; **128**: 871-881
- 13 **Ohlsson H**, Karlsson K, Edlund T. IPF1, a homeodomain-containing transactivator of the insulin gene. *EMBO J* 1993; **12**: 4251-4259
- 14 **Waeber G**, Thompson N, Nicod P, Bonny C. Transcriptional activation of the GLUT2 gene by the IPF-1/STF-1/IDX-1 homeobox factor. *Mol Endocrinol* 1996; **10**: 1327-1334
- 15 **Watada H**, Kajimoto Y, Umayahara Y, Matsuoka T, Kaneto H, Fujitani Y, Kamada T, Kawamori R, Yamasaki Y. The human glucokinase gene beta-cell-type promoter: an essential role of insulin promoter factor 1/PDX-1 in its activation in HIT-T15 cells. *Diabetes* 1996; **45**: 1478-1488
- 16 **Carty MD**, Lillquist JS, Peshavaria M, Stein R, Soeller WC. Identification of cis- and trans-active factors regulating human islet amyloid polypeptide gene expression in pancreatic beta-cells. *J Biol Chem* 1997; **272**: 11986-11993
- 17 **Leonard J**, Peers B, Johnson T, Ferreri K, Lee S, Montminy MR. Characterization of somatostatin transactivating factor-1, a novel homeobox factor that stimulates somatostatin expression in pancreatic islet cells. *Mol Endocrinol* 1993; **7**: 1275-1283
- 18 **Jonsson J**, Carlsson L, Edlund T, Edlund H. Insulin-promoter-factor 1 is required for pancreas development in mice. *Nature* 1994; **371**: 606-609
- 19 **Ahlgren U**, Jonsson J, Jonsson L, Simu K, Edlund H. Beta -Cell-specific inactivation of the mouse *Ipfl/Pdx1* gene results in loss of the beta -cell phenotype and maturity onset diabetes. *Genes Dev* 1998; **12**: 1763-1768
- 20 **Stoffers DA**, Zinkin NT, Stanojevic V, Clarke WL, Habener JF. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. *Nat Genet* 1997; **15**: 106-110
- 21 **Ferber S**, Halkin A, Cohen H, Ber I, Einav Y, Goldberg I, Barshack I, Seiffers R, Kopolovic J, Kaiser N, Karasik A. Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia. *Nat Med* 2000; **6**: 568-572
- 22 **Ber I**, Shternhall K, Perl S, Ohanuna Z, Goldberg I, Barshack I, Benvenisti-Zarum L, Meivar-Levy I, Ferber S. Functional, persistent, and extended liver to pancreas transdifferentiation. *J Biol Chem* 2003; **278**: 31950-31957
- 23 **Kojima H**, Fujimiya M, Matsumura K, Younan P, Imaeda H, Maeda M, Chan L. NeuroD-beta-cellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice. *Nat Med* 2003; **9**: 596-603
- 24 **Horb ME**, Shen CN, Tosh D, Slack JM. Experimental conversion of liver to pancreas. *Curr Biol* 2003; **13**: 105-115
- 25 **Watada H**, Kajimoto Y, Miyagawa J, Hanafusa T, Hamaguchi K, Matsuoka T, Yamamoto K, Matsuzawa Y, Kawamori R, Yamasaki Y. PDX-1 induces insulin and glucokinase gene expressions in alphaTC1 clone 6 cells in the presence of beta-cellulin. *Diabetes* 1996; **45**: 1826-1831
- 26 **Gittes GK**, Galante PE, Hanahan D, Rutter WJ, Debase HT. Lineage-specific morphogenesis in the developing pancreas: role of mesenchymal factors. *Development* 1996; **122**: 439-447
- 27 **Yang L**, Li S, Hatch H, Ahrens K, Cornelius JG, Petersen BE, Peck AB. *In vitro* trans-differentiation of adult hepatic stem cells into pancreatic endocrine hormone-producing cells. *Proc Natl Acad Sci USA* 2002; **99**: 8078-8083
- 28 **Ohneda K**, Ee H, German M. Regulation of insulin gene transcription. *Semin Cell Dev Biol* 2000; **11**: 227-233
- 29 **Matsuoka TA**, Zhao L, Artner I, Jarrett HW, Friedman D, Means A, Stein R. Members of the large Maf transcription family regulate insulin gene transcription in islet beta cells. *Mol Cell Biol* 2003; **23**: 6049-6062
- 30 **Kojima H**, Nakamura T, Fujita Y, Kishi A, Fujimiya M, Yamada S, Kudo M, Nishio Y, Maegawa H, Haneda M, Yasuda H, Kojima I, Seno M, Wong NC, Kikkawa R, Kashiwagi A. Combined expression of pancreatic duodenal homeobox 1 and islet factor 1 induces immature enterocytes to produce insulin. *Diabetes* 2002; **51**: 1398-1408